natgillin/translations-raw huggingface dataset:
Close monitoring of anticoagulation levels is warranted. 
Natančno je potrebno spremljati antikoagulacijo.
What you need to know before you take Nevirapine Teva Do not take Nevirapine Teva 
Kaj morate vedeti, preden boste vzeli zdravilo Nevirapin Teva Ne jemljite tablet Nevirapin Teva:
Nevirapine Teva is indicated for the treatment of HIV-1 infected adults, adolescents, and children of any age. 
Zdravilo Nevirapin Teva je indicirano za zdravljenje s HIV-1 okuženih odraslih, mladostnikov in otrok vseh starosti.
The frequencies estimated are based on pooled clinical study data for adverse reactions considered related to nevirapine treatment. 
Ocena pogostnosti temelji na zbirnih podatkih iz kliničnih študijah o neželenih učinkih, za katere so menili, da so povezani z zdravljenjem z zdravilom nevirapinom.
They should be advised to promptly notify their physician of any rash and avoid delay between the initial symptoms and medical consultation. 
Svetovati jim je potrebno, naj zdravnika obvestijo o vsakem izpuščaju in ob pojavu začetnih simptomov ne odlagajo obiska pri zdravniku.
No changes to lamivudine apparent clearance and volume of distribution, suggesting no induction effect of nevirapine on lamivudine clearance. 
Ni sprememb navideznega očistka lamivudina in volumna porazdelitve, kar kaže, da nevirapin nima
Nevirapine Teva should only be used with at least two other antiretroviral agents (see section 5.1). 
Zdravilo Nevirapin Teva se sme uporabljati samo hkrati z najmanj dvema drugima protivirusnima zdraviloma (glejte poglavje 5.1).
Nevirapine Teva may be taken with or without food. 
Zdravilo Nevirapin Teva lahko bolniki jemljejo s hrano ali brez nje.
Saquinavir/ritonavir The limited data available with saquinavir soft gel capsule boosted with ritonavir do not suggest any clinically relevant interaction between saquinavir boosted with ritonavir and nevirapine 
Sakvinavir/ritonavir Omejeno število podatkov, ki so na voljo o uporabi mehkih želatinskih kapsul sakvinavirja ob sočasnem jemanju ritonavirja, ne kaže na klinično pomembno interakcijo med sakvinavirjem ob sočasnem jemanju ritonavirja in nevirapina.
Nevirapine must not be readministered to patients who have required permanent discontinuation for clinical hepatitis due to nevirapine. 
Nevirapina ne smemo ponovno dajati bolnikom, katerim ga je bilo potrebno dokončno ukiniti zaradi klinične oblike hepatitisa, ki jo je povzročil nevirapin.
The first 18 weeks of treatment is a critical period which requires close monitoring. 
Prvih 18 tednov zdravljenja je kritično obdobje, v katerem je potrebno bolnika natančno spremljati.
Use caution when engaging in activities such as driving, using any tools or machines. 
Bodite previdni pri dejavnostih, kot so vožnja in delo z orodji ali s stroji.
Physicians needing to treat patients co-infected with tuberculosis and using a Nevirapine Teva containing regimen may consider coadministration of rifabutin instead. 
Zdravniki, ki zdravijo bolnike s sočasno okužbo s tuberkulozo in v sklopu zdravljenja uporabljajo zdravilo Nevirapin Teva, lahko presodijo o sočasnem dajanju z rifabutinom.
- The other ingredients are microcrystalline cellulose, lactose monohydrate, povidone K25, sodium starch glycolate (Type A), colloidal silicon dioxide and magnesium stearate. 
- Druge pomožne snovi so: mikrokristalna celuloza, laktoza (v obliki monohidrata), povidon K25, natrijev karboksimetilškrob (tip A), koloidni silicijev dioksid, magnezijev stearat.
By stopping reverse transcriptase from working, Nevirapine Teva helps control HIV-1 infection. 
S tem, ko ustavi delovanje reverzne transkriptaze, zdravilo Nevirapine Teva pomaga nadzorovati okužbo s HIV
Methadone-maintained patients beginning Nevirapine Teva therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly. 
Bolnike na metadonu, pri katerih uvedemo zdravljenje z zdravilom Nevirapin Teva, je potrebno spremljati, da bi odkrili znake odtegnitve, in odmerek metadona ustrezno prilagoditi.
Depending on the outcome your doctor may decide to interrupt or stop your Nevirapine Teva treatment. 
Glede na izvide se lahko odloči za prekinitev ali ukinitev zdravljenja z zdravilom Nevirapin Teva.
They should be informed that occurrence of symptoms suggestive of hepatitis should lead them to discontinue nevirapine and immediately seek medical evaluation, which should include liver function tests. 
Poučiti jih je potrebno, da morajo ob pojavu simptomov, ki kažejo na hepatitis, nevirapin prenehati jemati in pridobiti takojšnjo zdravniško oceno njihovega zdravstvenega stanja, ki mora vključevati tudi preiskave jetrnega delovanja.
Peak plasma nevirapine concentrations of 2 ± 0.4 μg/ml (7.5 μM) were attained by 4 hours following a single 200 mg dose. 
Največje koncentracije nevirapina v plazmi v višini 2 ± 0,4 μg/ml (7,5 μM) so izmerili 4 ure po dajanju enkratnega odmerka po 200 mg.
Contents of the pack and other information What Nevirapine Teva contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Nevirapin Teva
If ASAT or ALAT ≥ 2.5 ULN before or during treatment, then liver tests should be monitored more frequently during regular clinic visits. 
Če je raven AST ali ALT pred zdravljenjem ali med njim povečana na ≥ 2,5-kratno zgornjo mejno vrednost, je potrebno jetrne preiskave ob rednih kontrolnih pregledih opravljati pogosteje.
If ASAT or ALAT increase to > 5 ULN during treatment, nevirapine should be immediately stopped. 
Če se raven AST ali ALT med zdravljenjem poveča na > 5-kratno zgornjo mejo normalne vrednosti, je potrebno zdravljenje z nevirapinom nemudoma ukiniti.
Nevirapine Teva should not be used as the sole active antiretroviral, as monotherapy with any antiretroviral has shown to result in viral resistance. 
Zdravila Nevirapin Teva se ne sme uporabljati kot edino aktivno protiretrovirusno zdravilo, ker se je pokazalo, da se pri monoterapiji s katerimkoli protiretrovirusnim zdravilom razvije virusna odpornost.
Osteonecrosis: Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART). 
Osteonekroza: Čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredujočo boleznijo HIV ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART - combination antiretroviral therapy) ali obojim.
(0.2 %), angioedema, urticaria 
(0,2 %), angioedem, urtikarija
Uncommon Stevens-Johnson syndrome/toxic epidermal necrolysis (which may be fatal) 
Stevens-Johnsonov sindrom/toksična epidermalna nekroliza (ki sta lahko usodna)
The first 18 weeks of treatment is a critical period which requires close monitoring (see section 4.4). 
Prvih 18 tednov je kritično obdobje, v katerem moramo bolnika skrbno spremljati (glejte poglavje 4.4).
If you forget to take Nevirapine Teva 
Če ste pozabili vzeti zdravilo Nevirapin Teva
Nevirapine had no antiviral activity in cell culture against group O HIV-1 isolates or HIV-2 isolates. 
Nevirapin v celični kulturi ni učinkoval protivirusno na izolate HIV-1 iz skupine O ali izolate
The predetermined primary efficacy comparison was between the nevirapine twice daily and the efavirenz treatment groups. 
Vnaprej opredeljena primarna primerjava za oceno učinkovitosti je potekala med skupinama, kjer je prva prejemala nevirapin dvakrat na dan, druga pa efavirenz.
Renal dysfunction: The single-dose pharmacokinetics of nevirapine has been compared in 23 patients with either mild (50 ≤ CLcr < 80 ml/min), moderate (30 ≤ CLcr < 50 ml/min) or severe renal dysfunction (CLcr < 30 ml/min), renal impairment or end-stage renal disease (ESRD) requiring dialysis, and 8 patients with normal renal function (CLcr > 80 ml/min). 
Motnje ledvične funkcije: Farmakokinetiko nevirapina so po enkratnem odmerku primerjali pri 23 bolnikih z blago (50 ≤ CLcr < 80 ml/min), zmerno (30 ≤ CLcr < 50 ml/min) ali hudo motnjo ledvične funkcije (CLcr < 30 ml/min), ledvično okvaro ali ledvično boleznijo v končni fazi, ki je zahtevala dializo, ter pri 8 osebah z normalno ledvično funkcijo (CLcr > 80 ml/min).
Monotherapy with nevirapine has been associated with the development of NNRTI resistance. 
Monoterapijo z nevirapinom povezujejo z razvojem odpornosti proti NNRTI.
Talk to your doctor or pharmacist before taking Nevirapine Teva During the first 18 weeks of treatment with Nevirapine Teva it is very important that you and your doctor watch out for signs of liver or skin reactions. 
Prvih 18 tednov zdravljenja z zdravilom Nevirapin Teva je zelo pomembno, da ste vi in vaš zdravnik pozorni na znake jetrnih ali kožnih reakcij.
Tell your doctor immediately if you experience rash and any of the other side effects of a hypersensitivity (allergic) reaction. 
Svojega zdravnika nemudoma obvestite, če se pri vas pojavi izpuščaj in katerikoli drugi neželeni učinek, ki je posledica preobčutljivostne reakcije.
For children under 16 years of age who weigh less than 50 kg or whose body surface area is below 1.25 m2 other nevirapine containing oral formulations are available and should be used if appropriate. 
Za otroke, stare manj kot 16 let, ki tehtajo manj kot 50 kg ali katerih telesna površina je manjša od 1,25 m2, so na voljo tudi druge peroralne farmacevtske oblike, ki vsebujejo nevirapin in jih je treba uporabiti, če je primerno.
An increased risk was observed in men with detectable HIV-1 RNA in plasma and CD4 counts > 400 cells/mm3 (6.3 % versus 1.2 % for men with CD4 counts < 400 cells/mm3). 
Povečano tveganje so zasledili tudi pri moških z izmerljivo ravnijo HIV-1 RNA v plazmi in s številom celic CD4 > 400 celic/mm3 (6,3 % proti 1,2 % pri moških s številom celic CD4 < 400 celic/mm3).
Therefore, patients should be monitored carefully for the appearance of rash during this period. 
Zato je potrebno bolnike v tem obdobju skrbno opazovati, če se je pri njih pojavil izpuščaj.
The pharmacokinetics of autoinduction is characterised by an approximately 1.5 to 2 fold increase in the apparent oral clearance of nevirapine as treatment continues from a single dose to two-to-four weeks of dosing with 200-400 mg/day. 
Za farmakokinetiko samoindukcije je značilno približno 1,5- do 2-kratno povečanje navideznega očistka peroralnega nevirapina, ko zdravljenje z začetnim enkratnim odmerkom nadaljujemo dva do štiri tedne z odmerki po 200 do 400 mg na dan.
Methadone Individual Patient Dosing 
Metadon, individualni odmerki
Data reported in the literature from 20 HIV-infected patients suggest a steady state Cmax of 5.74 μg/ml (5.00-7.44) and Cmin of 3.73 μg/ml (3.20-5.08) with an AUC of 109.0 h*μg/ml (96.0-143.5) in patients taking 200 mg of nevirapine bid. 
okuženih bolnikov kažejo, da je Cmax v ravnovesnem stanju 5,74 μg/ml (5,00 do 7,44), Cmin 3,73 μg/ml (3,20 do 5,08) in AUC 109,0 h*μg/ml (96,0 do 143,5) pri bolnikih, ki jemljejo po 200 mg nevirapina
The dose of Nevirapine Teva may need adjusting. 
Odmerek zdravila Nevirapin Teva je včasih potrebno prilagoditi.
Elderly Nevirapine has not been specifically investigated in patients over the age of 65. 
Z nevirapinom niso izvajali specifičnih raziskav pri starejših bolnikih od 65 let.
Nevirapine: Zidovudine had no effect on its pharmacokinetics. 
Nevirapin: zidovudin ni vplival na njegovo farmakokinetiko.
compared with historical data where nevirapine was administered alone. 
v primerjavi s prejšnjimi podatki, ki so veljali za samostojno uporabo nevirapina.
There is not enough evidence to substantiate that the absence of an increased risk for toxicity seen in pretreated women initiating nevirapine with an undetectable viral load (less than 50 copies/ml of HIV-1 in plasma) and CD4 cell counts above 250 cells/mm3 also applies to pregnant women. 
Na voljo ni dovolj dokazov za trditev, da odsotnost povečanega tveganja za toksičnost pri že zdravljenih ženskah, ki imajo ob uvedbi nevirapina neizmerljivo virusno breme (manj kot 50 kopij/ml HIV-1 v plazmi) in število celic CD4 nad 250 celic/mm3 velja tudi za nosečnice.
Nevirapine Teva is not a cure for HIV infection. 
Zdravilo Nevirapin Teva ne ozdravi okužbe s HIV.
Other medicines and Nevirapine Teva 
Druga zdravila in zdravilo Nevirapin Teva
Nevirapine Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children of any age (see section 4.2). 
Zdravilo Nevirapin Teva je v kombinaciji z drugimi protiretrovirusnimi zdravili indicirano za zdravljenje s HIV-1 okuženih odraslih, mladostnikov in otrok vseh starosti (glejte poglavje 4.4.
Patients developing signs or symptoms of hepatitis, severe skin reaction or hypersensitivity reactions must discontinue nevirapine and seek medical evaluation immediately. 
Bolniki, pri katerih se razvijejo znaki ali simptomi hepatitisa, hude kožne reakcije ali preobčutljivostne reakcije, morajo prenehati jemati nevirapin, njihovo stanje pa mora nemudoma oceniti zdravnik.
Nevirapine Teva should be administered by physicians who are experienced in the treatment of HIV infection. 
Zdravilo Nevirapin Teva lahko dajejo zdravniki, ki imajo izkušnje z zdravljenjem okužbe s HIV.
The NEFA study is a controlled prospective randomised study which evaluated treatment options for patients who switch from protease inhibitor (PI) based regimen with undetectable load to either nevirapine, efavirenz or abacavir. 
Študija NEFA je nadzorovana, prospektivna študija z naključno izbiro bolnikov, v kateri so ocenjevali možne načine zdravljenja bolnikov z nedokazljivim bremenom, pri katerih zamenjajo zaviralec proteaze za nevirapin, efavirenz ali abakavir.
In ACTG 245, a double-blind placebo controlled study, the frequency of serious medicinal product-related granulocytopenia was 5/305 (1.6 %). 
V dvojno slepi s placebom nadzorovani raziskavi ACTG 245 so resno, z zdravilom povezano, granulocitopenijo zasledili pri 5 od 305 bolnikov (1,6 %).
Only a small fraction (< 5 %) of the radioactivity in urine (representing < 3 % of the total dose) was made up of parent compound; therefore, renal excretion plays a minor role in elimination of the parent compound. 
Samo majhna frakcija (< 5 %) radioaktivnosti v seču (< 3 % skupnega odmerka) je bila iz matične spojine.
Following intravenous administration to healthy adults, the volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 l/kg, suggesting that nevirapine is widely distributed in humans. 
Po intravenskem vnosu zdravim odraslim je bil volumen porazdelitve (Vdss) nevirapina 1,21 ± 0,09 l/kg,
Asymptomatic elevations of liver enzymes are frequently described and are not necessarily a contraindication to use nevirapine. 
Pogosto opisujejo pojav nesimptomatičnega povečanja jetrnih encimov, ki pa ni vedno kontraindikacija uporabe nevirapina.
The study randomly assigned 460 adults who were taking two nucleoside reverse-transcriptase inhibitors and at least one PI and whose plasma HIV-1 RNA levels had been less than 200 c/ml for at least the previous six months to switch from the PI to nevirapine (155 patients), efavirenz (156), or abacavir (149). 
V študijo so naključno sprejeli 460 odraslih, ki so jemali dva nukleozidna zaviralca reverzne transkriptaze in najmanj enega zaviralca proteaze, in pri katerih je bila plazemska koncentracija HIV-1 RNA manj kot 200 kopij/ml vsaj preteklih šest mesecev pred zamenjavo zaviralca proteaze za nevirapin (155 bolnikov), efavirenz (156) ali abakavir (149).
Investigations Common liver function tests abnormal (alanine aminotransferase increased; transaminases increased; aspartate aminotransferase increased; gamma-glutamyltransferase increased; hepatic enzyme increased; hypertransaminasaemia) Uncommon blood phosphorus decreased; blood pressure increased 
Preiskave pogosti nenormalen izvid jetrnih preiskav (povečana raven alanin-aminotransferaze; povečana raven transaminaz; povečana raven aspartat-aminotransferaze; povečana raven gama-glutamil-transferaze; povečana raven jetrnih encimov;
An increase in the dose of lopinavir/ritonavir to 533/133 mg (4 capsules) or 500/125 mg (5 tablets with 100/25 mg each) twice daily with food is recommended in combination with Nevirapine Teva. 
ritonavir do 533/133 mg (4 kapsule) ali 500/125 mg (5 tablet po 100/25 mg) 2-krat na dan ob jedi.
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions. 
Pri bolnikih s kroničnim hepatitisom B ali C, ki prejemajo kombinirano protivirusno zdravljenje, je prisotno povečano tveganje hudih neželenih učinkov na jetra, ki so lahko tudi smrtno nevarni.
The following adverse reactions which may be causally related to the administration of nevirapine have been reported. 
Poročila navajajo naslednje neželene učinke, ki so lahko vzročno povezani z dajanjem nevirapina.
The results suggest that supplementing nevirapine therapy with an additional 200 mg dose of nevirapine following each dialysis treatment would help offset the effects of dialysis on nevirapine clearance. 
Rezultati kažejo, da lahko z dodatnim odmerkom po 200 mg nevirapina po vsaki dializi uravnamo njen učinek na očistek nevirapina.
If you are receiving post-menopausal hormone therapy, ask your doctor for advice before taking this medicine. 
Če dobivate nadomestno hormonsko zdravljenje v pomenopavzi, se posvetujte s svojim zdravnikom preden boste vzeli to zdravilo.
However, the risk of any hepatic event continues past this period and monitoring should continue at frequent intervals. 
Tveganje za jetrne dogodke je možno tudi po tem obdobju, zato je potrebno s pogostim spremljanjem nadaljevati.
Hormonal methods of birth control other than Depot-medroxyprogesterone acetate (DMPA) should not be used as the sole method of contraception in women taking Nevirapine Teva, since nevirapine might lower the plasma concentrations of these medicinal products. 
Ženske, ki jemljejo zdravilo Nevirapin Teva, ne smejo uporabljati hormonskih metod za preprečevanje zanositve, razen depo-medroksiprogesteron acetata (DMPA), kot edino metodo kontracepcije, ker lahko nevirapin zmanjša koncentracijo zdravila v plazmi.
Significantly fewer patients in the abacavir group (9 patients, or 6%) than in the nevirapine group (26 patients, or 17%) or the efavirenz group (27 patients, or 17%) discontinued the medicinal product because of adverse events. 
V skupini z abakavirjem jih je značilno manj bolnikov (9 bolnikov ali 6 %) prenehalo jemati zdravilo zaradi neželenih učinkov kot v skupini z nevirapinom (26 bolnikov ali 17 %) ali efavirenzem (27
There are no restrictions on taking Nevirapine Teva with food and drink. 
Za jemanje zdravila Nevirapin Teva s hrano in pijačo ni nobenih omejitev.
Nevirapine is contraindicated in patients with severe hepatic impairment (Child-Pugh C, see section 4.3). 
Nevirapin je kontraindicirano pri bolnikih s hudo jetrno okvaro (Child-Pugh C, glejte poglavje 4.3).
Increased ASAT or ALAT levels ≥ 2.5 ULN and/or co-infection with hepatitis B and/or C at the start of antiretroviral therapy is associated with greater risk of hepatic adverse reactions during antiretroviral therapy in general, including nevirapine containing regimens. 
Povečana raven AST ali ALT na ≥ 2,5-kratno zgornjo mejo normalne laboratorijske vrednosti in/ali sočasna okužba z virusom hepatitisa B ali C ali oboje na začetku protivirusnega zdravljenja sta na splošno povezani z večjim tveganjem neželenih učinkov na jetra med protivirusnim zdravljenjem, tudi s takšnim, ki vključuje nevirapin.
Pharmacokinetic results suggest caution should be exercised when nevirapine is administered to patients with moderate hepatic dysfunction (Child-Pugh B). 
Farmakokinetični podatki kažejo, da je pri uporabi nevirapina pri bolnikih z zmerno jetrno disfunkcijo (Child-Pugh B), potrebna previdnost.
The nevirapine twice daily regimen and the efavirenz regimen were not significantly different (p= 0.091) in terms of efficacy as measured by treatment failure, or any component of treatment failure including virological failure. 
Režim z dvema odmerkoma nevirapina in režim z efavirenzem se po učinkovitosti, določeni na podlagi neuspeha zdravljenja, ali katerekoli sestavine neuspeha zdravljenja, vključno z virološkim neuspehom.
1,216 antiretroviral-therapy naïve patients with plasma HIV-1 RNA > 5,000 copies/ml at baseline were assigned to nevirapine 400 mg once daily, nevirapine 200 mg twice daily, efavirenz 600 mg once daily, or nevirapine (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine for 48 weeks. 
1216 bolnikov, ki se še niso zdravili s protiretrovirusnimi zdravili in so imeli izhodiščno plazemsko koncentracijo HIV-1 RNA > 5000 kopij/ml so razvrstili v skupine zdravljenje z nevirapinom po 400 mg enkrat na dan ali po 200 mg dvakrat na dan, efavirenzem po 600 mg enkrat na dan ali nevirapinom (400 mg) in efavirenzem (800 mg) enkrat na dan, skupaj s stavudinom in lamivudinom, ki je trajalo 48 tednov.
The most frequently reported adverse reactions related to nevirapine therapy, across all clinical studies, were rash, allergic reactions, hepatitis, abnormal liver function tests, nausea, vomiting, diarrhoea, abdominal pain, fatigue, fever, headache and myalgia. 
Neželene reakcije o katerih so najpogosteje poročali v povezavi z zdravljenjem z nevirapinom, so bili v vseh kliničnih študijah izpuščaj, alergijske reakcije, hepatitis, nenormalni jetrni izvidi, slabost, bruhanje, driska, trebušna bolečina, utrujenost, vročina, glavobol in mialgija.
Taking all doses at the appropriate times: - greatly increases the effectiveness of your combination antiretroviral medicines. 
Če ste prenehali jemati zdravilo Nevirapin Teva Redno jemanje odmerkov ob ustreznem času: - zelo poveča učinkovitost vam predpisane kombinacije protiretrovirusnih zdravil,
Contains lactose: see leaflet for further information. 
Vsebuje laktozo: pred uporabo preberite priloženo navodilo!
Currently available data on pregnant women indicate no malformative or foeto/ neonatal toxicity. 
Nosečnost Razpoložljivi podatki pri nosečnicah ne kažejo na anomalije ali okvare pri zarodku oziroma novorojenčku zaradi toksičnosti.
Contact your doctor if you notice changes in body fat (see section 4 “Possible side effects”). 
Če opazite spremembe telesnega maščevja, se pogovorite z zdravnikom (glejte poglavje »Neželeni učinki«).
Patients experiencing rash during the 14-day lead-in period of 200 mg/day should not have their Nevirapine Teva dose increased until the rash has resolved. 
Pri bolnikih, pri katerih se med 14-dnevnim uvajalnim obdobjem z odmerki po 200 mg na dan pojavi izpuščaj, odmerka zdravila Nevirapin Teva ne smemo povečati, dokler izpuščaj ne izzveni.
Adult patients: 
Starejši bolniki
Blood and lymphatic system disorders Common granulocytopenia Uncommon anaemia 
Bolezni krvi in limfatičnega sistema pogosti granulocitopenija občasni anemija
Gastrointestinal disorders Common nausea, vomiting, abdominal pain, diarrhoea Hepatobiliary disorders Common hepatitis (including severe and life-threatening hepatotoxicity) (1.9%) Uncommon jaundice 
Bolezni prebavil pogosti slabost, bruhanje, driska, trebušna bolečina Bolezni jeter, žolčnika in žolčevodov pogosti hepatitis (tudi huda in življenjsko nevarna hepatotoksičnost) (1,9 %)
Women have a three fold higher risk than men for symptomatic, often rash-associated, hepatic events (5.8 % versus 2.2 %), and treatment-naïve patients of either gender with detectable HIV-1 RNA in plasma with higher CD4 counts at initiation of nevirapine therapy are at higher risk for symptomatic hepatic events with nevirapine. 
Pri ženskah je tveganje simptomatskih jetrnih dogodkov ob uporabi nevirapina, ki jih pogosto spremlja izpuščaj, trikrat večje kot pri moških (5,8 % proti 2,2 %), pri prvič zdravljenih bolnikih obeh spolov, ki imajo v plazmi izmerljivo raven HIV1RNA in pri bolnikih z večjim številom celic CD4 je v uvajalnem obdobju zdravljenja z nevirapinom povečano tveganje simptomatskih jetrnih dogodkov.